Benitec Biopharma Inc. (BNTC) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Benitec Biopharma Inc. on September 10, 2025. The filing addresses a material accounting error discovered during the preparation of the Annual Report on Form 10-K for the fiscal year ended June 30, 2025.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or debt figures. The disclosed financial impact is qualitative, noting that the error resulted in the understatement of share-based compensation expense, additional paid-in capital, accumulated deficit, net loss, and loss per share.
Material Changes and Accounting Error
- Non-Reliance on Prior Statements: The Audit Committee concluded that the unaudited consolidated financial statements for the quarters ended December 31, 2024, and March 31, 2025, should no longer be relied upon.
- Cause of Error: The error stemmed from the migration of equity awards data to a new information recording system in November 2023. The system was incorrectly configured, leading to the under-recording of non-cash share-based compensation expenses.
- Materiality: While the impact was immaterial to periods prior to the quarter ended December 31, 2024, the cumulative effect was material to the financial statements for the quarters ended December 31, 2024, and March 31, 2025.
Outlook, Management Commentary, and Risks
Management and the Audit Committee have discussed the matter with the independent registered public accounting firm, Baker Tilly US, LLP. The Company is preparing restatements of the affected prior financial statements to be included in the upcoming 2025 Form 10-K. The Company expects to file the 2025 Form 10-K on a timely basis, on or prior to the regulatory deadline. The filing includes standard forward-looking statement disclaimers regarding risks and uncertainties.
Investor Verification Checklist
- Verify the magnitude of the restatement adjustments once the 2025 Form 10-K is filed.
- Confirm the revised net loss and loss per share figures for the quarters ended December 31, 2024, and March 31, 2025.
- Monitor the filing status of the 2025 Form 10-K to ensure it is submitted by the deadline.
- Review the "Risk Factors" section of the most recent 10-K for additional context on operational and financial risks.